-
1.
Fonseca NA, Rodrigues AS, Rodrigues-Santos P, Alves V, Gregorio AC, Valerio-Fernandes A, et al. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination. Biomaterials. 2015;69:76-88. doi: 10.1016/j.biomaterials.2015.08.007. [PubMed: 26283155].
-
2.
Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov. 2014;13(7):497-512. doi: 10.1038/nrd4253. [PubMed: 24981363]. [PubMed Central: PMC4234172].
-
3.
Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol. 2009;86(3):151-64. doi: 10.1016/j.yexmp.2009.01.004. [PubMed: 19454272]. [PubMed Central: PMC2716701].
-
4.
Zhang Y, Lai BS, Juhas M. Recent advances in aptamer discovery and applications. Molecules. 2019;24(5). doi: 10.3390/molecules24050941. [PubMed: 30866536]. [PubMed Central: PMC6429292].
-
5.
Bates PJ, Reyes-Reyes, Elsa M M, Mohammad T, Murphy EM, O'Toole, et al. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms. Biochim Biophys Acta Gen Subj. 2017;1861(5 Pt B):1414-28. doi: 10.1016/j.bbagen.2016.12.015. [PubMed: 28007579].
-
6.
Gonzalez V, Guo K, Hurley L, Sun D. Identification and characterization of nucleolin as a c-myc G-quadruplex-binding protein. J Biol Chem. 2009;284(35):23622-35. doi: 10.1074/jbc.M109.018028. [PubMed: 19581307]. [PubMed Central: PMC2749137].
-
7.
Reyes-Reyes EM, Teng Y, Bates PJ. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res. 2010;70(21):8617-29. doi: 10.1158/0008-5472.CAN-10-0920. [PubMed: 20861190]. [PubMed Central: PMC2970734].
-
8.
Sharma VR, Thomas SD, Miller DM, Rezzoug F. Nucleolin Overexpression Confers Increased Sensitivity to the Anti-Nucleolin Aptamer, AS1411. Cancer Invest. 2018;36(9-10):475-91. doi: 10.1080/07357907.2018.1527930. [PubMed: 30396283]. [PubMed Central: PMC6396827].
-
9.
Berger CM, Gaume X, Bouvet P. The roles of nucleolin subcellular localization in cancer. Biochimie. 2015;113:78-85. doi: 10.1016/j.biochi.2015.03.023. [PubMed: 25866190].
-
10.
Girvan AC, Teng Y, Casson LK, Thomas SD, Juliger S, Ball MW, et al. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. Mol Cancer Ther. 2006;5(7):1790-9. doi: 10.1158/1535-7163.MCT-05-0361. [PubMed: 16891465].
-
11.
Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 2008;68(7):2358-65. doi: 10.1158/0008-5472.CAN-07-5723. [PubMed: 18381443].
-
12.
Ugrinova I, Monier K, Ivaldi C, Thiry M, Storck S, Mongelard F, et al. Inactivation of nucleolin leads to nucleolar disruption, cell cycle arrest and defects in centrosome duplication. BMC Mol Biol. 2007;8:66. doi: 10.1186/1471-2199-8-66. [PubMed: 17692122]. [PubMed Central: PMC1976620].
-
13.
Teng Y, Girvan AC, Casson LK, Pierce WJ, Qian M, Thomas SD, et al. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res. 2007;67(21):10491-500. doi: 10.1158/0008-5472.CAN-06-4206. [PubMed: 17974993].
-
14.
Xiang D, Shigdar S, Qiao G, Zhou SF, Li Y, Wei MQ, et al. Aptamer-mediated cancer gene therapy. Curr Gene Ther. 2015;15(2):109-19. doi: 10.2174/1566523214666141224095105. [PubMed: 25537777].
-
15.
Xiang D, Shigdar S, Qiao G, Wang T, Kouzani AZ, Zhou SF, et al. Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine. Theranostics. 2015;5(1):23-42. doi: 10.7150/thno.10202. [PubMed: 25553096]. [PubMed Central: PMC4265746].
-
16.
Thiel KW, Hernandez LI, Dassie JP, Thiel WH, Liu X, Stockdale KR, et al. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res. 2012;40(13):6319-37. doi: 10.1093/nar/gks294. [PubMed: 22467215]. [PubMed Central: PMC3401474].
-
17.
Yabbarov NG, Posypanova GA, Vorontsov EA, Obydenny SI, Severin ES. A new system for targeted delivery of doxorubicin into tumor cells. J Control Release. 2013;168(2):135-41. doi: 10.1016/j.jconrel.2013.03.007. [PubMed: 23517785].
-
18.
Zhang J, Chen R, Fang X, Chen F, Wang Y, Chen M. Nucleolin targeting AS1411 aptamer modified pH-sensitive micelles for enhanced delivery and antitumor efficacy of paclitaxel. Nano Res. 2015;8(1):201-18. doi: 10.1007/s12274-014-0619-4.
-
19.
Luo Z, Yan Z, Jin K, Pang Q, Jiang T, Lu H, et al. Precise glioblastoma targeting by AS1411 aptamer-functionalized poly (l-gamma-glutamylglutamine)-paclitaxel nanoconjugates. J Colloid Interface Sci. 2017;490:783-96. doi: 10.1016/j.jcis.2016.12.004. [PubMed: 27988470].
-
20.
Zhang F, Correia A, Makila E, Li W, Salonen J, Hirvonen JJ, et al. Receptor-mediated surface charge inversion platform based on porous silicon nanoparticles for efficient cancer cell recognition and combination therapy. ACS Appl Mater Interfaces. 2017;9(11):10034-46. doi: 10.1021/acsami.7b02196. [PubMed: 28248078].
-
21.
Plosker GL. Pegylated liposomal doxorubicin: A review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs. 2008;68(17):2535-51. doi: 10.2165/0003495-200868170-00008. [PubMed: 19016577].
-
22.
Liao ZX, Chuang EY, Lin CC, Ho YC, Lin KJ, Cheng PY, et al. An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance. J Control Release. 2015;208:42-51. doi: 10.1016/j.jconrel.2015.01.032. [PubMed: 25637705].
-
23.
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102. doi: 10.1186/1556-276X-8-102. [PubMed: 23432972]. [PubMed Central: PMC3599573].
-
24.
Chen KJ, Liang HF, Chen HL, Wang Y, Cheng PY, Liu HL, et al. A thermoresponsive bubble-generating liposomal system for triggering localized extracellular drug delivery. ACS Nano. 2013;7(1):438-46. doi: 10.1021/nn304474j. [PubMed: 23240550].
-
25.
Wang Z, Xia J, Cai F, Zhang F, Yang M, Bi S, et al. Aptamer-functionalized hydrogel as effective anti-cancer drugs delivery agents. Colloids Surf B Biointerfaces. 2015;134:40-6. doi: 10.1016/j.colsurfb.2015.06.031. [PubMed: 26142627].
-
26.
Ischakov R, Adler-Abramovich L, Buzhansky L, Shekhter T, Gazit E. Peptide-based hydrogel nanoparticles as effective drug delivery agents. Bioorg Med Chem. 2013;21(12):3517-22. doi: 10.1016/j.bmc.2013.03.012. [PubMed: 23566763].
-
27.
Alibolandi M, Ramezani M, Abnous K, Hadizadeh F. AS1411 aptamer-decorated biodegradable polyethylene glycol-poly(lactic-co-glycolic acid) nanopolymersomes for the targeted delivery of gemcitabine to non-small cell lung cancer in vitro. J Pharm Sci. 2016;105(5):1741-50. doi: 10.1016/j.xphs.2016.02.021. [PubMed: 27039356].
-
28.
Alibolandi M, Taghdisi SM, Ramezani P, Hosseini Shamili F, Farzad SA, Abnous K, et al. Smart AS1411-aptamer conjugated pegylated PAMAM dendrimer for the superior delivery of camptothecin to colon adenocarcinoma in vitro and in vivo. Int J Pharm. 2017;519(1-2):352-64. doi: 10.1016/j.ijpharm.2017.01.044. [PubMed: 28126548].
-
29.
Barzegar Behrooz A, Nabavizadeh F, Adiban J, Shafiee Ardestani M, Vahabpour R, Aghasadeghi MR, et al. Smart bomb AS1411 aptamer-functionalized/PAMAM dendrimer nanocarriers for targeted drug delivery in the treatment of gastric cancer. Clin Exp Pharmacol Physiol. 2017;44(1):41-51. doi: 10.1111/1440-1681.12670. [PubMed: 27626786].
-
30.
Mohammadzadeh P, Cohan RA, Ghoreishi SM, Bitarafan-Rajabi A, Ardestani MS. AS1411 Aptamer-Anionic Linear Globular Dendrimer G2-Iohexol Selective Nano-Theranostics. Sci Rep. 2017;7(1):11832. doi: 10.1038/s41598-017-12150-8. [PubMed: 28928437]. [PubMed Central: PMC5605695].
-
31.
Mosafer J, Teymouri M, Abnous K, Tafaghodi M, Ramezani M. Study and evaluation of nucleolin-targeted delivery of magnetic PLGA-PEG nanospheres loaded with doxorubicin to C6 glioma cells compared with low nucleolin-expressing L929 cells. Mater Sci Eng C Mater Biol Appl. 2017;72:123-33. doi: 10.1016/j.msec.2016.11.053. [PubMed: 28024568].
-
32.
Wang C, Liu B, Xu X, Zhuang B, Li H, Yin J, et al. Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine. Oncotarget. 2016;7(7):8360-72. doi: 10.18632/oncotarget.7073. [PubMed: 26840019]. [PubMed Central: PMC4884998].
-
33.
Xu G, Yu X, Zhang J, Sheng Y, Liu G, Tao W, et al. Robust aptamer-polydopamine-functionalized M-PLGA-TPGS nanoparticles for targeted delivery of docetaxel and enhanced cervical cancer therapy. Int J Nanomedicine. 2016;11:2953-65. doi: 10.2147/IJN.S103513. [PubMed: 27382282]. [PubMed Central: PMC4922762].
-
34.
Qi J, Zhang Y, Gou Y, Lee P, Wang J, Chen S, et al. Multidrug delivery systems based on human serum albumin for combination therapy with three anticancer agents. Mol Pharm. 2016;13(9):3098-105. doi: 10.1021/acs.molpharmaceut.6b00277. [PubMed: 27453125].
-
35.
Tao W, Zeng X, Wu J, Zhu X, Yu X, Zhang X, et al. Polydopamine-based surface modification of novel nanoparticle-aptamer bioconjugates for in vivo breast cancer targeting and enhanced therapeutic effects. Theranostics. 2016;6(4):470-84. doi: 10.7150/thno.14184. [PubMed: 26941841]. [PubMed Central: PMC4775858].
-
36.
Chen D, Li B, Cai S, Wang P, Peng S, Sheng Y, et al. Dual targeting luminescent gold nanoclusters for tumor imaging and deep tissue therapy. Biomaterials. 2016;100:1-16. doi: 10.1016/j.biomaterials.2016.05.017. [PubMed: 27236844].
-
37.
Murphy EM, Centner CS, Bates PJ, Malik MT, Kopechek JA. Delivery of thymoquinone to cancer cells with as1411-conjugated nanodroplets. PLoS One. 2020;15(5):233466. doi: 10.1371/journal.pone.0233466. [PubMed: 32437399]. [PubMed Central: PMC7241745].
-
38.
Taghdisi SM, Danesh NM, Ramezani M, Lavaee P, Jalalian SH, Robati RY, et al. Double targeting and aptamer-assisted controlled release delivery of epirubicin to cancer cells by aptamers-based dendrimer in vitro and in vivo. Eur J Pharm Biopharm. 2016;102:152-8. doi: 10.1016/j.ejpb.2016.03.013. [PubMed: 26987703].
-
39.
Li X, Zhu X, Qiu L. Constructing aptamer anchored nanovesicles for enhanced tumor penetration and cellular uptake of water soluble chemotherapeutics. Acta Biomater. 2016;35:269-79. doi: 10.1016/j.actbio.2016.02.012. [PubMed: 26873366].
-
40.
Sakhtianchi R, Darvishi B, Mirzaie Z, Dorkoosh F, Shanehsazzadeh S, Dinarvand R. Pegylated magnetic mesoporous silica nanoparticles decorated with AS1411 Aptamer as a targeting delivery system for cytotoxic agents. Pharm Dev Technol. 2019;24(9):1063-75. doi: 10.1080/10837450.2019.1569678. [PubMed: 30654677].
-
41.
Zhu YJ, Li WJ, Hong ZY, Tang AN, Kong DM. Stable, polyvalent aptamer-conjugated near-infrared fluorescent nanocomposite for high-performance cancer cell-targeted imaging and therapy. J Mater Chem B. 2017;5(46):9229-37. doi: 10.1039/c7tb02218b. [PubMed: 32264606].
-
42.
Hashii N, Suzuki J, Hanamatsu H, Furukawa JI, Ishii-Watabe A. In-depth site-specific O-Glycosylation analysis of therapeutic Fc-fusion protein by electron-transfer/higher-energy collisional dissociation mass spectrometry. Biologicals. 2019;58:35-43. doi: 10.1016/j.biologicals.2019.01.005. [PubMed: 30704904].
-
43.
Riccardi C, Fabrega C, Grijalvo S, Vitiello G, D'Errico G, Eritja R, et al. AS1411-decorated niosomes as effective nanocarriers for Ru(iii)-based drugs in anticancer strategies. J Mater Chem B. 2018;6(33):5368-84. doi: 10.1039/c8tb01563e. [PubMed: 32254501].
-
44.
Xing H, Tang L, Yang X, Hwang K, Wang W, Yin Q, et al. Selective delivery of an anticancer drug with aptamer-functionalized liposomes to breast cancer cells in vitro and in vivo. J Mater Chem B. 2013;1(39):5288-97. doi: 10.1039/C3TB20412J. [PubMed: 24159374]. [PubMed Central: PMC3800741].
-
45.
Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006;6(7):559-65. doi: 10.1038/nrc1891. [PubMed: 16794638].
-
46.
Dhez AC, Benedetti E, Antonosante A, Panella G, Ranieri B, Florio TM, et al. Targeted therapy of human glioblastoma via delivery of a toxin through a peptide directed to cell surface nucleolin. J Cell Physiol. 2018;233(5):4091-105. doi: 10.1002/jcp.26205. [PubMed: 28941284].
-
47.
Rajabnejad SH, Mokhtarzadeh A, Abnous K, Taghdisi SM, Ramezani M, Razavi BM. Targeted delivery of melittin to cancer cells by AS1411 anti-nucleolin aptamer. Drug Dev Ind Pharm. 2018;44(6):982-7. doi: 10.1080/03639045.2018.1427760. [PubMed: 29325460].
-
48.
Gajski G, Garaj-Vrhovac V. Melittin: A lytic peptide with anticancer properties. Environ Toxicol Pharmacol. 2013;36(2):697-705. doi: 10.1016/j.etap.2013.06.009. [PubMed: 23892471].
-
49.
Yangyuoru PM, Bradburn DA, Liu Z, Xiao TS, Russell R. The G-quadruplex (G4) resolvase DHX36 efficiently and specifically disrupts DNA G4s via a translocation-based helicase mechanism. J Biol Chem. 2018;293(6):1924-32. doi: 10.1074/jbc.M117.815076. [PubMed: 29269411]. [PubMed Central: PMC5808756].
-
50.
Romano S, Fonseca N, Simoes S, Goncalves J, Moreira JN. Nucleolin-based targeting strategies for cancer therapy: from targeted drug delivery to cytotoxic ligands. Drug Discov Today. 2019;24(10):1985-2001. doi: 10.1016/j.drudis.2019.06.018. [PubMed: 31271738].
LEAVE A COMMENT HERE: